Enliven Therapeutics reported second quarter financial results for the period ended June 30, 2026. The company posted a net loss of $32.5 million and research and development expenses of $29.0 million. As of June 30, Enliven held $895.2 million in cash, cash equivalents, and marketable securities, providing a runway into 2030. Clinically, the company announced positive Phase 1 data for ELVN-001 in chronic myeloid leukemia (CML), showing a 61% overall major molecular response rate at the 80 mg dose. Enliven reached alignment with the FDA on key Phase 3 trial design components and received Fast Track designation for ELVN-001. The company expects to initiate the ENABLE-2 Phase 3 trial in the second half of 2026. Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics.
